Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Kainos HIV Candidate Leaps Ahead In China Under Priority Review

Executive Summary

Kainos Medicine's HIV drug candidate KM-023 is set to move directly into a Phase III program in China through local licensee Jiangsu Aidea, benefiting from the country's fast-track review system and accelerating the development of the drug, which Kainos sees as bringing multiple possible benefits over existing therapies. 

You may also be interested in...



Interview: Kainos Aims To Open New Era With Novel Parkinson’s Drug

Kainos Medicine’s senior vice president sat down with Scrip to talk about the progress and ambitions for its first-in-class, potentially disease modifying Parkinson's disease drug candidate. If the drug candidate successfully goes through a Phase IIa in the US, it is set to draw robust interest from multinational pharmas which are already active in the area that lacks fundamental treatments.

Korean Bio/Healthcare Sector Sees Ample Fund Inflows In 2021

Financing for Korean bioventures and pharma firms remained strong this year amid ample liquidity and strong investor sentiment in the sector. SK Bioscience's IPO was the top fundraiser in 2021, followed by HK inno.N’s offering, while GI Innovation raised the most money from venture capital sources.

Deal Watch: Sanofi To Tap Owkin’s AI, Machine Learning In Oncology

French pharma makes $180m equity investment in Owkin under collaboration targeting four cancer types. Pyramid gets global license to MPS1 precision cancer candidate from Voronoi.

Topics

Related Companies

UsernamePublicRestriction

Register

SC124089

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel